Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Diabetes Reports
Erschienen in: Current Diabetes Reports 7/2015

01.07.2015 | Microvascular Complications—Nephropathy (T Isakova, Section Editor)

Genetics of Diabetic Nephropathy: a Long Road of Discovery

verfasst von: Amy Jayne McKnight, Seamus Duffy, Alexander P. Maxwell

Erschienen in: Current Diabetes Reports | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

The global prevalence of diabetic nephropathy is rising in parallel with the increasing incidence of diabetes in most countries. Unfortunately, up to 40 % of persons diagnosed with diabetes may develop kidney complications. Diabetic nephropathy is associated with substantially increased risks of cardiovascular disease and premature mortality. An inherited susceptibility to diabetic nephropathy exists, and progress is being made unravelling the genetic basis for nephropathy thanks to international research collaborations, shared biological resources and new analytical approaches. Multiple epidemiological studies have highlighted the clinical heterogeneity of nephropathy and the need for better phenotyping to help define important subgroups for analysis and increase the power of genetic studies. Collaborative genome-wide association studies for nephropathy have reported unique genes, highlighted novel biological pathways and suggested new disease mechanisms, but progress towards clinically relevant risk prediction models for diabetic nephropathy has been slow. This review summarises the current status, recent developments and ongoing challenges elucidating the genetics of diabetic nephropathy.
Literatur
1.
2.
3.
Hex N, Bartlett C, Wright D, et al. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29(7):855–62.PubMed
4.
5.
Ali MK, Bullard KM, Gregg EW, et al. A cascade of care for diabetes in the United States: visualizing the gaps. Ann Intern Med. 2014;161(10):681–9.PubMed
6.
American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36(4):1033–46.PubMedCentral
7.
Gilg J, Pruthi R, Fogarty D. UK renal registry 17th annual report: chapter 1 UK renal replacement therapy incidence in 2013: national and centre-specific analyses. Nephron Physiol. 2015;129 Suppl 1:1–29.
8.
9.
10.
11.
Coresh J, Turin TC, Matsushita K, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014;311(24):2518–31.PubMed
12.
Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380(9854):1662–73.PubMedCentralPubMed
13.
Hill CJ, Cardwell CR, Patterson CC, et al. Chronic kidney disease and diabetes in the national health service: a cross-sectional survey of the U.K. National Diabetes Audit. Diabet Med. 2014;31(4):448–54.PubMed
14.
Ho K, McKnight AJ. The changing landscape of diabetic kidney disease: new reflections on phenotype, classification, and disease progression to influence future investigative studies and therapeutic trials. Adv Chronic Kidney Dis. 2014;21(3):256–9.PubMed
15.••
Marshall SM. Natural history and clinical characteristics of CKD in type 1 and type 2 diabetes mellitus. Adv Chronic Kidney Dis. 2014;21(3):267–72. Comprehensive review explaining the challenges of assigning clinical phenotypes for kidney disease in individuals with diabetes. PubMed
16.
Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med. 1984;311(2):89–93.PubMed
17.
Andersen AR, Christiansen JS, Andersen JK, et al. Diabetic nephropathy in type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia. 1983;25(6):496–501.PubMed
18.
Borch-Johnsen K, Andersen PK, Deckert T. The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1985;28(8):590–6.PubMed
19.
Marshall SM. Diabetic nephropathy in type 1 diabetes: has the outlook improved since the 1980s? Diabetologia. 2012;55(9):2301–6.PubMed
20.
Mogensen CE, Keane WF, Bennett PH, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet. 1995;346(8982):1080–4.PubMed
21.
Viberti GC, Hill RD, Jarrett RJ, et al. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet. 1982;1(8287):1430–2.PubMed
22.
Parving HH, Persson F, Rossing P. Microalbuminuria: a parameter that has changed diabetes care. Diabetes Res Clin Pract. 2015;107(1):1–8.PubMed
23.
Perkins BA, Ficociello LH, Silva KH, et al. Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 2003;348(23):2285–93.PubMed
24.
Perkins BA, Ficociello LH, Roshan B, et al. In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int. 2010;77(1):57–64.PubMedCentralPubMed
25.
Caramori ML, Fioretto P, Mauer M. Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions. Diabetes. 2003;52(4):1036–40.PubMed
26.
Najafian B, Alpers CE, Fogo AB. Pathology of human diabetic nephropathy. Contrib Nephrol. 2011;170:36–47.PubMed
27.
Tervaert TW, Mooyaart AL, Amann K, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010;21(4):556–63.PubMed
28.
Mazzucco G, Bertani T, Fortunato M, et al. Different patterns of renal damage in type 2 diabetes mellitus: a multicentric study on 393 biopsies. Am J Kidney Dis. 2002;39(4):713–20.PubMed
29.
Bell S, Fletcher EH, Brady I, et al. End-stage renal disease and survival in people with diabetes: a national database linkage study. QJM. 2015;108(2):127–34.PubMedCentralPubMed
30.
Chan Y, Lim ET, Sandholm N, et al. An excess of risk-increasing low-frequency variants can be a signal of polygenic inheritance in complex diseases. Am J Hum Genet. 2014;94(3):437–52.PubMedCentralPubMed
31.
Placha G, Canani LH, Warram JH, et al. Evidence for different susceptibility genes for proteinuria and ESRD in type 2 diabetes. Adv Chronic Kidney Dis. 2005;12(2):155–69.PubMed
32.
Kottgen A, Pattaro C, Boger CA, et al. New loci associated with kidney function and chronic kidney disease. Nat Genet. 2010;42(5):376–84.PubMedCentralPubMed
33.
Sandholm N, Forsblom C, Makinen VP, et al. Genome-wide association study of urinary albumin excretion rate in patients with type 1 diabetes. Diabetologia. 2014;57(6):1143–53.PubMed
34.••
Sandholm N, McKnight AJ, Salem RM, et al. Chromosome 2q31.1 associates with ESRD in women with type 1 diabetes. J Am Soc Nephrol. 2013;24(10):1537–43. First identification of gender-specific SNP with genome-wide significance for diabetic nephropathy.PubMedCentralPubMed
35.
Canani LH, Gerchman F, Gross JL. Familial clustering of diabetic nephropathy in Brazilian type 2 diabetic patients. Diabetes. 1999;48(4):909–13.PubMed
36.
Skrunes R, Svarstad E, Reisaeter AV, et al. Familial clustering of ESRD in the Norwegian population. Clin J Am Soc Nephrol. 2014;9(10):1692–700.PubMed
37.
Spray BJ, Atassi NG, Tuttle AB, et al. Familial risk, age at onset, and cause of end-stage renal disease in white Americans. J Am Soc Nephrol. 1995;5(10):1806–10.PubMed
38.
Thameem F, Kawalit IA, Adler SG, et al. Susceptibility gene search for nephropathy and related traits in Mexican-Americans. Mol Biol Rep. 2013;40(10):5769–79.PubMedCentralPubMed
39.
Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63(1):225–32.PubMed
40.
DCCT Research. Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977–86.
41.
Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383–93.PubMed
42.
Forsblom CM, Kanninen T, Lehtovirta M, et al. Heritability of albumin excretion rate in families of patients with type II diabetes. Diabetologia. 1999;42(11):1359–66.PubMed
43.
Fogarty DG, Rich SS, Hanna L, et al. Urinary albumin excretion in families with type 2 diabetes is heritable and genetically correlated to blood pressure. Kidney Int. 2000;57(1):250–7.PubMed
44.
Langefeld CD, Beck SR, Bowden DW, et al. Heritability of GFR and albuminuria in Caucasians with type 2 diabetes mellitus. Am J Kidney Dis. 2004;43(5):796–800.PubMed
45.
MacCluer JW, Scavini M, Shah VO, et al. Heritability of measures of kidney disease among Zuni Indians: the Zuni Kidney Project. Am J Kidney Dis. 2010;56(2):289–302.PubMedCentralPubMed
46.
Harjutsalo V, Groop PH. Epidemiology and risk factors for diabetic kidney disease. Adv Chronic Kidney Dis. 2014;21(3):260–6.PubMed
47.
Bell CG, Teschendorff AE, Rakyan VK, et al. Genome-wide DNA methylation analysis for diabetic nephropathy in type 1 diabetes mellitus. BMC Med Genomics. 2010;3:33.PubMedCentralPubMed
48.
Gu T, Gu HF, Hilding A, et al. Increased DNA methylation levels of the insulin-like growth factor binding protein 1 gene are associated with type 2 diabetes in Swedish men. Clin Epigenetics. 2013;5(1):21.PubMedCentralPubMed
49.
Rakyan VK, Beyan H, Down TA, et al. Identification of type 1 diabetes-associated DNA methylation variable positions that precede disease diagnosis. PLoS Genet. 2011;7(9):e1002300.PubMedCentralPubMed
50.
McKnight AJ, McKay GJ, Maxwell AP. Genetic and epigenetic risk factors for diabetic kidney disease. Adv Chron Kidney Dis. 2014;21(3):287–96.
51.
McKnight AJ, O’Donoghue D, Peter MA. Annotated chromosome maps for renal disease. Hum Mutat. 2009;30(3):314–20.PubMed
52.
Nazir N, Siddiqui K, Al-Qasim S, et al. Meta-analysis of diabetic nephropathy associated genetic variants in inflammation and angiogenesis involved in different biochemical pathways. BMC Med Genet. 2014;15(1):103.PubMedCentralPubMed
53.
Tong Z, Yang Z, Patel S, et al. Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc Natl Acad Sci U S A. 2008;105(19):6998–7003.PubMedCentralPubMed
54.
Williams WW, Salem RM, McKnight AJ, et al. Association testing of previously reported variants in a large case-control meta-analysis of diabetic nephropathy. Diabetes. 2012;61(8):2187–94.PubMedCentralPubMed
55.
McKnight AJ, Currie D, Maxwell AP. Unravelling the genetic basis of renal diseases; from single gene to multifactorial disorders. J Pathol. 2010;220(2):198–216.PubMed
56.
Pezzolesi MG, Krolewski AS. The genetic risk of kidney disease in type 2 diabetes. Med Clin N Am. 2013;97(1):91–107.PubMedCentralPubMed
57.
Igo Jr RP, Iyengar SK, Nicholas SB, et al. Genomewide linkage scan for diabetic renal failure and albuminuria: the FIND study. Am J Nephrol. 2011;33(5):381–9.PubMedCentralPubMed
58.
Thameem F, Igo Jr RP, Freedman BI, et al. A genome-wide search for linkage of estimated glomerular filtration rate (eGFR) in the Family Investigation of Nephropathy and Diabetes (FIND). PLoS One. 2013;8(12):e81888.PubMedCentralPubMed
59.
Mahajan A, Sim X, Ng HJ, et al. Identification and functional characterization of G6PC2 coding variants influencing glycemic traits define an effector transcript at the G6PC2-ABCB11 locus. PLoS Genet. 2015;11(1):e1004876.PubMedCentralPubMed
60.
Palmer ND, Goodarzi MO, Langefeld CD et al. Genetic variants associated with quantitative glucose homeostasis traits translate to type 2 diabetes in Mexican Americans: the GUARDIAN (Genetics Underlying Diabetes in Hispanics) Consortium. Diabetes 2014.
61.
Kuchenbaecker KB, Ramus SJ, Tyrer J, et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet. 2015;47(2):164–71.PubMed
62.
Al Olama AA, Kote-Jarai Z, Berndt SI, et al. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet. 2014;46(10):1103–9.PubMedCentralPubMed
63.
Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet. 2013;45(12):1452–8.PubMedCentralPubMed
64.
Ha NT, Freytag S, Bickeboeller H. Coverage and efficiency in current SNP chips. Eur J Hum Genet. 2014;22(9):1124–30.PubMed
65.
Little J, Higgins JP, Ioannidis JP, et al. STrengthening the REporting of Genetic Association Studies (STREGA): an extension of the STROBE statement. PLoS Med. 2009;6(2):e22.PubMed
66.
Winkler TW, Day FR, Croteau-Chonka DC, et al. Quality control and conduct of genome-wide association meta-analyses. Nat Protoc. 2014;9(5):1192–212.PubMedCentralPubMed
67.
Feehally J, Farrall M, Boland A, et al. HLA has strongest association with IgA nephropathy in genome-wide analysis. J Am Soc Nephrol. 2010;21(10):1791–7.PubMedCentralPubMed
68.
Kiryluk K, Li Y, Scolari F, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet. 2014;46(11):1187–96.PubMedCentralPubMed
69.
Stanescu HC, Arcos-Burgos M, Medlar A, et al. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med. 2011;364(7):616–26.PubMed
70.
Genovese G, Tonna SJ, Knob AU, et al. A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9. Kidney Int. 2010;78(7):698–704.PubMedCentralPubMed
71.
Kopp JB, Smith MW, Nelson GW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet. 2008;40(10):1175–84.PubMedCentralPubMed
72.
Kottgen A, Glazer NL, Dehghan A, et al. Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet. 2009;41(6):712–7.PubMedCentralPubMed
73.
Liu CT, Garnaas MK, Tin A, et al. Genetic association for renal traits among participants of African ancestry reveals new loci for renal function. PLoS Genet. 2011;7(9):e1002264.PubMedCentralPubMed
74.
Kao WH, Klag MJ, Meoni LA, et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet. 2008;40(10):1185–92.PubMed
75.••
Sandholm N, Salem RM, McKnight AJ, et al. New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet. 2012;8(9):e1002921. Largest meta-analysis of GWAS conducted for diabetic nephropathy with replication confirming significant SNPs. PubMedCentralPubMed
76.
Shimazaki A, Kawamura Y, Kanazawa A, et al. Genetic variations in the gene encoding ELMO1 are associated with susceptibility to diabetic nephropathy. Diabetes. 2005;54(4):1171–8.PubMed
77.
Hanson RL, Millis MP, Young NJ, et al. ELMO1 variants and susceptibility to diabetic nephropathy in American Indians. Mol Genet Metab. 2010;101(4):383–90.PubMed
78.
Leak TS, Perlegas PS, Smith SG, et al. Variants in intron 13 of the ELMO1 gene are associated with diabetic nephropathy in African Americans. Ann Hum Genet. 2009;73(2):152–9.PubMedCentralPubMed
79.
Pezzolesi MG, Katavetin P, Kure M, et al. Confirmation of genetic associations at ELMO1 in the GoKinD collection supports its role as a susceptibility gene in diabetic nephropathy. Diabetes. 2009;58(11):2698–702.PubMedCentralPubMed
80.
Wu HY, Wang Y, Chen M, et al. Association of ELMO1 gene polymorphisms with diabetic nephropathy in Chinese population. J Endocrinol Invest. 2013;36(5):298–302.PubMed
81.
Yadav AK, Kumar V, Dutta P, et al. Variations in CCR5, but not HFE, ELMO1, or SLC12A3, are associated with susceptibility to kidney disease in north Indian individuals with type 2 diabetes CCR5HFEELMO1SLC12A32. J Diabetes. 2014;6(6):547–55.PubMed
82.
Franceschini N, Shara NM, Wang H, et al. The association of genetic variants of type 2 diabetes with kidney function. Kidney Int. 2012;82(2):220–5.PubMedCentralPubMed
83.
Hanson RL, Craig DW, Millis MP, et al. Identification of PVT1 as a candidate gene for end-stage renal disease in type 2 diabetes using a pooling-based genome-wide single nucleotide polymorphism association study. Diabetes. 2007;56(4):975–83.PubMed
84.
McDonough CW, Palmer ND, Hicks PJ, et al. A genome-wide association study for diabetic nephropathy genes in African Americans. Kidney Int. 2011;79(5):563–72.PubMedCentralPubMed
85.
Ebers GC, Sadovnik AD. Re: GAMES issue. J Neuroimmunol. 2004;153(1–2):4–5.PubMed
86.
McKnight AJ, Maxwell AP, Sawcer S, et al. A genome-wide DNA microsatellite association screen to identify chromosomal regions harboring candidate genes in diabetic nephropathy. J Am Soc Nephrol. 2006;17(3):831–6.PubMed
87.
Craig DW, Millis MP, DiStefano JK. Genome-wide SNP genotyping study using pooled DNA to identify candidate markers mediating susceptibility to end-stage renal disease attributed to type 1 diabetes. Diabet Med. 2009;26(11):1090–8.PubMed
88.
Pezzolesi MG, Poznik GD, Mychaleckyj JC, et al. Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. Diabetes. 2009;58(6):1403–10.PubMedCentralPubMed
89.
Palmer ND, Ng MC, Hicks PJ, et al. Evaluation of candidate nephropathy susceptibility genes in a genome-wide association study of African American diabetic kidney disease. PLoS One. 2014;9(2):e88273.PubMedCentralPubMed
90.
Martini S, Nair V, Patel SR, et al. From single nucleotide polymorphism to transcriptional mechanism: a model for FRMD3 in diabetic nephropathy. Diabetes. 2013;62(7):2605–12.PubMedCentralPubMed
91.
Tryka KA, Hao L, Sturcke A, et al. NCBI’s database of Genotypes and Phenotypes: dbGaP. Nucleic Acids Res. 2014;42(Database issue):D975–9.PubMedCentralPubMed
92.
Maeda S, Imamura M, Kurashige M, et al. Replication study for the association of 3 SNP loci identified in a genome-wide association study for diabetic nephropathy in European type 1 diabetes with diabetic nephropathy in Japanese patients with type 2 diabetes. Clin Exp Nephrol. 2013;17(6):866–71.PubMed
93.
Sambo F, Malovini A, Sandholm N, et al. Novel genetic susceptibility loci for diabetic end-stage renal disease identified through robust naive Bayes classification. Diabetologia. 2014;57(8):1611–22.PubMed
94.
Germain M, Pezzolesi MG, Sandholm N, et al. SORBS1 gene, a new candidate for diabetic nephropathy: results from a multi-stage genome-wide association study in patients with type 1 diabetes. Diabetologia. 2015;58(3):543–8.PubMed
95.
Lettre G, Jackson AU, Gieger C, et al. Identification of ten loci associated with height highlights new biological pathways in human growth. Nat Genet. 2008;40(5):584–91.PubMedCentralPubMed
96.
Lango AH, Estrada K, Lettre G, et al. Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature. 2010;467(7317):832–8.
97.
Wood AR, Esko T, Yang J, et al. Defining the role of common variation in the genomic and biological architecture of adult human height. Nat Genet. 2014;46(11):1173–86.PubMedCentralPubMed
98.
Harjutsalo V, Maric C, Forsblom C, et al. Sex-related differences in the long-term risk of microvascular complications by age at onset of type 1 diabetes. Diabetologia. 2011;54(8):1992–9.PubMed
99.
Charchar FJ, Bloomer LD, Barnes TA, et al. Inheritance of coronary artery disease in men: an analysis of the role of the Y chromosome. Lancet. 2012;379(9819):915–22.PubMedCentralPubMed
100.
Sharma K, Karl B, Mathew AV, et al. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. J Am Soc Nephrol. 2013;24(11):1901–12.PubMedCentralPubMed
101.
Higgins GC, Coughlan MT. Mitochondrial dysfunction and mitophagy: the beginning and end to diabetic nephropathy? Br J Pharmacol. 2014;171(8):1917–42.PubMedCentralPubMed
102.
Swan EJ, Salem RM, Sandholm N et al. Genetic risk factors affecting mitochondrial function are associated with kidney disease in individuals with type 1 diabetes. Diabet Med 2015.
103.
Swan EJ, Maxwell AP, McKnight AJ. Distinct methylation patterns in genes that affect mitochondrial function are associated with kidney disease in blood-derived DNA from individuals with type 1 diabetes. Diabet Med 2015.
104.
Douglas AP, Vance DR, Kenny EM, et al. Next-generation sequencing of the mitochondrial genome and association with IgA nephropathy in a renal transplant population. Sci Rep. 2014;4:7379.PubMedCentralPubMed
105.
McKnight AJ, Maxwell AP. Bioinformatic Resources for Diabetic Nephropathy. J Diabetes Bioinforma. 2013;1(1):11–8.
106.
Martini S, Nair V, Keller BJ, et al. Integrative biology identifies shared transcriptional networks in CKD. J Am Soc Nephrol. 2014;25(11):2559–72.PubMed
107.
Brennan EP, Morine MJ, Walsh DW, et al. Next-generation sequencing identifies TGF-beta1-associated gene expression profiles in renal epithelial cells reiterated in human diabetic nephropathy. Biochim Biophys Acta. 2012;1822(4):589–99.PubMedCentralPubMed
108.
Liu R, Zhong Y, Li X, et al. Role of transcription factor acetylation in diabetic kidney disease. Diabetes. 2014;63(7):2440–53.PubMed
109.
Miao F, Chen Z, Genuth S, et al. Evaluating the role of epigenetic histone modifications in the metabolic memory of type 1 diabetes. Diabetes. 2014;63(5):1748–62.PubMedCentralPubMed
110.
Reddy MA, Sumanth P, Lanting L, et al. Losartan reverses permissive epigenetic changes in renal glomeruli of diabetic db/db mice. Kidney Int. 2014;85(2):362–73.PubMedCentralPubMed
111.
Kato M, Zhang J, Wang M, et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A. 2007;104(9):3432–7.PubMedCentralPubMed
112.
Zhou Q, Chung AC, Huang XR, et al. Identification of novel long noncoding RNAs associated with TGF-beta/Smad3-mediated renal inflammation and fibrosis by RNA sequencing. Am J Pathol. 2014;184(2):409–17.PubMed
113.
Zhou J, Peng R, Li T, et al. A potentially functional polymorphism in the regulatory region of let-7a-2 is associated with an increased risk for diabetic nephropathy. Gene. 2013;527(2):456–61.PubMed
114.
Smyth LJ, McKay GJ, Maxwell AP, et al. DNA hypermethylation and DNA hypomethylation is present at different loci in chronic kidney disease. Epigenetics. 2014;9(3):366–76.PubMedCentralPubMed
115.
Zhang H, Cai X, Yi B, et al. Correlation of CTGF gene promoter methylation with CTGF expression in type 2 diabetes mellitus with or without nephropathy. Mol Med Rep. 2014;9(6):2138–44.PubMedCentralPubMed
116.
Sapienza C, Lee J, Powell J, et al. DNA methylation profiling identifies epigenetic differences between diabetes patients with ESRD and diabetes patients without nephropathy. Epigenetics. 2011;6(1):20–8.PubMed
117.
Hirayama A, Nakashima E, Sugimoto M, et al. Metabolic profiling reveals new serum biomarkers for differentiating diabetic nephropathy. Anal Bioanal Chem. 2012;404(10):3101–9.PubMed
118.
Pena MJ, Lambers Heerspink HJ, Hellemons ME, et al. Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with type 2 diabetes mellitus. Diabet Med. 2014;31(9):1138–47.PubMed
119.
Stec DF, Wang S, Stothers C, et al. Alterations of urinary metabolite profile in model diabetic nephropathy. Biochem Biophys Res Commun. 2015;456(2):610–4.PubMed
120.
Zubiri I, Posada-Ayala M, Sanz-Maroto A, et al. Diabetic nephropathy induces changes in the proteome of human urinary exosomes as revealed by label-free comparative analysis. J Proteomics. 2014;96:92–102.PubMed
121.
Caseiro A, Barros A, Ferreira R, et al. Pursuing type 1 diabetes mellitus and related complications through urinary proteomics. Transl Res. 2014;163(3):188–99.PubMed
122.
Zurbig P, Jerums G, Hovind P, et al. Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes. 2012;61(12):3304–13.PubMedCentralPubMed
123.
Locke AE, Kahalo B, Berndt SI, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518(7538):197–206.PubMedCentralPubMed
124.
Shungin D, Winkler TW, Croteau-Chonka DC, et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature. 2015;518(7538):187–96.PubMed
125.
Pers TH, Karjalainen JM, Chan Y, et al. Biological interpretation of genome-wide association studies using predicted gene functions. Nat Commun. 2015;6:5890.PubMedCentralPubMed
126.
Abecasis GR, Auton A, Brooks LD, et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491(7422):56–65.PubMed
127.
128.
McKnight AJ, Currie D, Patterson CC, et al. Targeted genome-wide investigation identifies novel SNPs associated with diabetic nephropathy. Hugo J. 2009;3(1–4):77–82.PubMedCentralPubMed
129.
Savage DA, Patterson CC, Deloukas P, et al. Genetic association analyses of non-synonymous single nucleotide polymorphisms in diabetic nephropathy. Diabetologia. 2008;51(11):1998–2002.PubMedCentralPubMed
130.
Cooke Bailey JN, Palmer ND, Ng MC, et al. Analysis of coding variants identified from exome sequencing resources for association with diabetic and non-diabetic nephropathy in African Americans. Hum Genet. 2014;133(6):769–79.PubMed
131.
Collins R. What makes UK Biobank special? Lancet. 2012;379(9822):1173–4.PubMed
132.
Kerr SM, Campbell A, Murphy L, et al. Pedigree and genotyping quality analyses of over 10,000 DNA samples from the Generation Scotland: Scottish Family Health Study. BMC Med Genet. 2013;14:38.PubMedCentralPubMed
133.
Zhang C, Pierce BL. Genetic susceptibility to accelerated cognitive decline in the US Health and Retirement Study. Neurobiol Aging. 2014;35(6):1512–8.
134.
Westra HJ, Peters MJ, Esko T, et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat Genet. 2013;45(10):1238–43.PubMedCentralPubMed
135.
Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 2012;40(Database issue):D930–4.PubMedCentralPubMed
136.
Mooyaart AL, Valk EJ, van Es LA, et al. Genetic associations in diabetic nephropathy: a meta-analysis. Diabetologia. 2014;57(3):650.
137.
Garcia DL, Anderson S, Rennke HG, Brenner BM. Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass. Proc Natl Acad Sci U S A. 1988;85(16):6142–6.PubMedCentralPubMed
138.
Veikkolainen V, Naillat F, Railo A, et al. ErbB4 modulates tubular cell polarity and lumen diameter during kidney development. J Am Soc Nephrol. 2012;23(1):112–22.PubMedCentralPubMed
139.
Zeng F, Zhang MZ, Singh AB, et al. ErbB4 isoforms selectively regulate growth factor induced Madin-Darby canine kidney cell tubulogenesis. Mol Biol Cell. 2007;18(11):4446–56.PubMedCentralPubMed
140.
Woroniecka KI, Park AS, Mohtat D, Thomas DB, Pullman JM, Susztak K. Transcriptome analysis of human diabetic kidney disease. Diabetes. 2011;60(9):2354–69.PubMedCentralPubMed
141.
Schmid H, Boucherot A, Yasuda Y, et al. Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes. 2006;55(11):2993–3003.PubMed
142.
Lin WH, Huang CJ, Liu MW, et al. Cloning, mapping, and characterization of the human sorbin and SH3 domain containing 1 (SORBS1) gene: a protein associated with c-Abl during insulin signaling in the hepatoma cell line Hep3B. Genomics. 2001;74(1):12–20.PubMed
143.
Nakatani S, Kakehashi A, Ishimura E et al. Targeted proteomics of isolated glomeruli from the kidneys of diabetic rats: sorbin and SH3 domain containing 2 is a novel protein associated with diabetic nephropathy. Exp Diabetes Res. 2011.
Metadaten
Titel
Genetics of Diabetic Nephropathy: a Long Road of Discovery
verfasst von
Amy Jayne McKnight
Seamus Duffy
Alexander P. Maxwell
Publikationsdatum
01.07.2015
Verlag
Springer US
Erschienen in
Current Diabetes Reports / Ausgabe 7/2015
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-015-0610-9

Weitere Artikel der Ausgabe 7/2015

Current Diabetes Reports 7/2015 Zur Ausgabe

Microvascular Complications—Nephropathy (T Isakova, Section Editor)

The Evolving Understanding of the Contribution of Lipid Metabolism to Diabetic Kidney Disease

Psychosocial Aspects (KK Hood and S Jaser, Section Editors)

Linking Community Resources in Diabetes Care: a Role for Technology?

Psychosocial Aspects (KK Hood and S Jaser, Section Editors)

Diabetes and Behavioral Learning Principles: Often Neglected yet Well-Known and Empirically Validated Means of Optimizing Diabetes Care Behavior

Immunology and Transplantation (A Pileggi, Section Editor)

Mesenchymal Stromal Cells to Halt the Progression of Type 1 Diabetes?

Genetics (AP Morris, Section Editor)

Genetics of Drug Response in Type 2 Diabetes

Microvascular Complications—Nephropathy (T Isakova, Section Editor)

Update on Glycemic Control for the Treatment of Diabetic Kidney Disease

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise